The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | The role of venetoclax in R/R MCL & options for patients who progress on venetoclax
Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the role of venetoclax in relapsed/refractory (R/R) mantle cell lymphoma (MCL) and highlights treatment options for patients who progress after venetoclax treatment. Dr Phillips explains that venetoclax is currently being explored in combination with ibrutinib in the second-line setting. For patients who progress on this agent in third line and beyond, CAR-T therapy with brexucabtagene autoleucel (brexu-cel) is a promising option. Dr Phillips also comments on the role of pirtobrutinib in this setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
